Loading
A phase 2 trial of EGCG and Quinine Sulfate Vaginal Suppository in vaginal cancer, run by Amplexd Therapeutics, Inc., now recruiting.
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities is a phase 2 interventional study registered as NCT07572396 by Amplexd Therapeutics, Inc., with 45 participants planned, started 2026-04-30 and due to reach its primary completion in 2026-12-27. Interventions recorded: EGCG and Quinine Sulfate Vaginal Suppository.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Shares Vaginal squamous cell carcinoma (HPV-associated), Vaginal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/